As the most common healthcare-related infection in intensive care units, and one of the most dreaded complications of in-hospital care, ventilator-associated pneumonia (VAP) is a cause for serious concern and demands meticulous care efforts to be taken. Pharm-Olam is proud to be partnering with a progressive drug development company in their search for a solution when a VAP diagnosis is made.
A Phase III study for the treatment of ventilator-associated pneumonia (VAP) in intensive care patients.
Sites & Locations:
120+ Sites across 25 countries in Asia, Eastern and Western Europe, and the Middle East
Site Identification & Selection
Clinical & Medical Monitoring
Learn the details by clicking on the image on the right.